Hematologic Oncology

Amitkumar Mehta, MD, discusses the rationale behind utilizing parsaclisib in relapsed or refractory mantle cell lymphoma as part of the phase 2 CITADEL-205 study.

Scott R. Solomon, MD, discusses the effects of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who were previously treated with CD19-directed therapies.

Rajneesh Nath, MD, discusses the interim results of the phase 3 SIERRA trial in patients with relapsed/refractory acute myeloid leukemia.

February 11, 2021 - Treatment with the first-generation precision cell therapy Orca-T led to a significant reduction in cases of graft-versus-host disease, an impressive GVHD relapse-free survival rate, a lack of treatment-related mortalities, while showcasing scalability potential.

February 11, 2021 - A conditioning regimen comprised of targeted radiation with Iomab-B led to a lower incidence of sepsis as well as trends toward reduced rates of severe mucositis and febrile neutropenia versus conventional care and standard conditioning regimens in older adults with relapsed or refractory acute myeloid leukemia.

February 11, 2021 — Apamistamab conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia.

February 10, 2021 - Hematopoietic recovery following myeloablative transplantation with omidubicel was faster than standard myeloablative umbilical cord blood transplantation and was associated with encouraging clinical benefit.

Anna Barata, PhD, discusses patient-reported toxicities with axicabtagene ciloleucel (axi-cel) in patients 1-year post-infusion.

YunZu Michele Wang, MD, discusses the potential utility of ruxolitinib in children and young adult patients with chronic graft-versus-host disease.

February 10, 2021 - Treatment with the investigative gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients less than 18 years of age with transfusion-dependent beta-thalassemia with a median average hemoglobin of 11.3 g/dL.

February 10, 2021 - CPX-351 demonstrated improved overall survival at 5 years versus standard 7+3 chemotherapy in older patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

February 10, 2021 - The JAK 1/2 inhibitor ruxolitinib, when given at a maximum dose of 10 mg peri-transplant, has been shown to be safe and feasible in patients with myelofibrosis.

Sikander Ailawadhi, MD, discusses the future of relapsed/refractory multiple myeloma, the potential for retreatment with proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, and the promise of T-cell engagers in the field.

Experts comment on the use of venetoclax-based therapy in treating chronic lymphocytic leukemia.

Experts Dr Stilgenbauer and Dr Ghia highlight and comment on the ECOG 1912 and iLLUMINATE trials.

February 9, 2021 - Responsiveness to treatment received immediately prior to CAR T-cell therapy may not be associated with post–CAR T outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma who receive axicabtagene ciloleucel.

Sairah Ahmed, MD, discusses the efficacy of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with refractory large B-cell lymphoma (LBCL) who achieved complete remission (CR) to any prior treatment versus those who were primary refractory.

Mitchell E. Horwitz, MD, discusses the use of omidubicel versus standard myeloablative umbilical cord blood transplant in patients with hematologic malignancies.

February 9, 2021 - The European Commission has granted a full marketing authorization for fedratinib for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocytopenia myelofibrosis who have not received JAK inhibitors or who have received ruxolitinib.

February 9, 2021 - Patients with refractory large B-cell lymphoma have less to gain from axicabtagene ciloleucel if they have never achieved a complete response to any line of prior therapy.